New use urged for Amgen drug
From Times Wire Services
A U.S. advisory panel unanimously urged regulators to approve an Amgen Inc. drug for a rare blood disorder that puts patients at risk of bleeding.
The Food and Drug Administration advisors said the benefits of Nplate outweighed the risks for treating chronic immune thrombocytopenia purpura.
The FDA usually follows the panel’s recommendations. Thousand Oaks-based Amgen said it expected a final ruling in the first half of this year.
